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Background: Information about drug-target relations is at the heart of drug discovery. There are now dozens of
databases providing drug-target interaction data with varying scope, and focus. Therefore, and due to the large
chemical space, the overlap of the different data sets is surprisingly small. As searching through these sources
manually is cumbersome, time-consuming and error-prone, integrating all the data is highly desirable. Despite a
few attempts, integration has been hampered by the diversity of descriptions of compounds, and by the fact that
the reported activity values, coming from different data sets, are not always directly comparable due to usage of
different metrics or data formats.
Description: We have built Drug2Gene, a knowledge base, which combines the compound/drug-gene/protein
information from 19 publicly available databases. A key feature is our rigorous unification and standardization
process which makes the data truly comparable on a large scale, allowing for the first time effective data mining in
such a large knowledge corpus. As of version 3.2, Drug2Gene contains 4,372,290 unified relations between
compounds and their targets most of which include reported bioactivity data. We extend this set with putative
(i.e. homology-inferred) relations where sufficient sequence homology between proteins suggests they may bind to
similar compounds. Drug2Gene provides powerful search functionalities, very flexible export procedures, and a
user-friendly web interface.
Conclusions: Drug2Gene v3.2 has become a mature and comprehensive knowledge base providing unified,
standardized drug-target related information gathered from publicly available data sources. It can be used to
integrate proprietary data sets with publicly available data sets. Its main goal is to be a ‘one-stop shop’ to identify
tool compounds targeting a given gene product or for finding all known targets of a drug. Drug2Gene with its
integrated data set of public compound-target relations is freely accessible without restrictions at http://www.
drug2gene.com.
Keywords: Drug-target relations, Compound-protein relations, Drug development, Drug discovery, Drug
repositioning, Knowledge base, Tool compounds, Biological effect, BioactivityBackground
High-throughput screening techniques caused a dramatic
increase in drug-target related information not only within
pharmaceutical companies but also in public databases.
For instance, as of September, 2013, ChEMBL [1] con-
tained 12,077,491 bioactivity evidences, 1,324,941 com-
pounds, and 9,356 protein targets [2]. BindingDB [3] grew
from around 20,000 drug-target binding activities in 2007
to 620,000 as of January 2013 [4] and the number of
relations in the current version 3 of DrugBank has* Correspondence: bertram.weiss@bayer.com
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unless otherwise stated.expanded by more than 50% compared to the previous
release [5]. Adequate consolidation and exploration of
this compound-gene relation space can have direct
impact on the different phases of the drug discovery
process by speeding up the identification of tool com-
pounds or by facilitating the repositioning of known
drugs [6]. To address this need there exist now numer-
ous databases like STITCH [7], SuperTarget [8], SLAP
[9], Dr. PIAS [10], PROMISCUOUS [11], DrugMap Cen-
tral [12], PiHelper [13], and ChemMapper [14] that offer
different levels of representation, curation and annotation
of relational data. For example STITCH is an online re-
source that focuses on interactions between proteins andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tween more than 300,000 compounds and 2,600,000 pro-
teins from 1,133 organisms, all extracted from source
databases like, ChEMBL, and BindingDB. In addition this
data is enriched with protein-protein interaction and bio-
logical pathway information.
The availability of such a considerable number of pro-
jects built upon the source databases confirms the need
of consolidation and improved representation of the
compound-target data. However, the scope and func-
tionality of the derived databases is oftentimes specific
(single purpose applications) and their data content may
not be standardized or normalized. The main motivation
to create Drug2Gene is to provide the largest, standard-
ized, and unified compound-target knowledge base that
eliminates redundancy to eventually enable effective data
mining of the drug-target space.Table 1 Drug2Gene data source statistics
Source database Genes/proteins Dr
CGDCP [17] 6071 311
ChEMBL [1] 5115 746
CTD [18] 27314 115
DrugBank [5] 3726 782
IUPHAR [19] 114 145
MICAD [20] 249 68
PDSP_Ki [21] 605 525
PharmGKB [22] 22677 363
TTD [23] 1518 241
Uniprot [24] 86605 369
Ligand Expo [25] - 751
HGNC [26] 24726 -
PDBsum [27] 23745 -
ChEBI [28] - 501
NCBI PubChem Compound [29] - 746
NCBI PubChem Substance [29] - 767
PubChem Bioassay [30] - -
Unified relations shared among two or more DBs - -
Total counts from all source databases 202465 231
NCBI Gene/Entrez Gene [15] Used for Unification/Dat
Homology inferred relations from NCBI
HomoloGene [15]
- -
Total relations in Drug2Gene including
homology-inferred relations
- -
Drug2Gene is built of three entities: genes, compounds, and relations between them
entities are listed by source database and by type of the extracted entity - genes, co
bases provide all three types of entries in their flat files. There are also only gene-ce
PubChem Compound, and NCBI PubChem Substance) source databases that provid
like Ligand Expo (links to proteins in PDBsum) and PubChem Bioassay (relations be
Compound/Substance). Only entries participating in a relation are counted in this ta
S2. Dataset - November 2013. The last column shows the number of relations after
unique to each source database.The Drug2Gene building process integrates data from
19 public bio- and chemo informatics resources, some
of which are integrated for the first time in a relation-
centered knowledge base. It removes redundancy in the
relational, target, and compound namespaces and also
facilitates the comparison of experimental data from
different sources by standardizing bioactivity data.
Drug2Gene enriches the combined dataset with add-
itional homology-based relations through the use of
gene homology groups from NCBI HomoloGene [15].
This relational data is paired with powerful search
functionality and a user-friendly web interface. Drug2-
Gene aims at being not only a starting point for, but
also a continuous companion during the drug discovery
process. Its relation-centered design concept keeps the
resource sparse on additional information about inter-
acting partners and instead provides external links tougs/compounds Relations/interactions Unique relations in DB
5 169154 154532 (3.534%)
582 2830526 2519174 (57.617%)
69 89094 70944 (1.623%)
5 17321 7338 (0.168%)
5 651 348 (0.008%)
70 55 (0.001%)
6 22790 11505 (0.263%)
0 78317 73064 (1.671%)
8 2599 1077 (0.025%)
3 351189 342495 (7.833%)












. The entities are extracted from 19 public source databases. Numbers of
mpounds, or relations. Most of the compound-target oriented (relational) data-
ntered (HGNC, PDBsum, and NCBI Gene) and compound-centered (ChEBI, NCBI
e only gene or compound entries. Their entities are linked by relational sources
tween genes in NCBI Gene and compounds/substances in NCBI PubChem
ble. For data regardless participation in relations, see Additional file 1: Table
data integration (and as percent of the total number of integrated relations)
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information.
Construction and content
The need for data integration
Due to the ever growing amount of published compound-
target interaction data large public compound-target data-
bases that use manual text-mining as their major data
source (BindingDB, ChEMBL) increase their coordination
efforts by concentrating on different sets of scientific jour-
nals [16]. As a result, the overlap between publicly avail-
able databases is constantly decreasing. Currently, several
source databases have to be searched to comprehensively
cover the publicly available drug-target space (see Table 1).
In addition, different databases tend to use different
naming schemes for genes and compounds and provide
measurements of the interaction data in different value
formats. As a consequence the search and subsequent
unification of the retrieved data requires a considerable
amount of time and is highly unpractical. Drug2Gene
tackles these problems by providing a single access point
to more than 4,000,000 publicly available compound-
target interactions. All source datasets are integrated in a
universal data structure and presented in a user interface
that provides and extends the essential functionalities of
the primary databases.
Drug2Gene entry: a compound, a gene, and the relation
between them
The concept of Drug2Gene is simple and organized
around three main types of entities that together makeFigure 1 A Drug2Gene entry. Conceptually, a Drug2Gene entry consists
several evidences. Evidences may come from one or more source database
descriptions. Each entry contains additional information about the unificati
Drug2Gene annotations.up a Drug2Gene entry: a compound, a gene, and a rela-
tion between them (see Figure 1). Such a relation may
be reported by more than one source database and may
be supported by more than one evidence. An evidence
can thereby be biological activity data, quantitative meas-
urement of binding affinity (i.e. the half maximal inhibitory
concentration - IC50, the absolute inhibition constant - Ki,
the dissociation constant - Kd), primary screening data (e.g.
activity at given concentration), or other types of qualita-
tive or quantitative data. A sentence or a paragraph from a
publication may also be considered an evidence (e.g. “Orli-
stat is a new inhibitor of pancreatic lipase enzyme.”). Thus,
the major function of a Drug2Gene entry is to integrate
the relational, compound, and genetic entities from source
databases by merging actually identical entries and to ag-
gregate all evidences supporting this relation irrespectively
of data formats and in how many different primary data-
bases they had been reported.
Integration of primary databases into Drug2Gene entries
In its current version (3.2) Drug2Gene has integrated 19
publicly available source databases (Table 1). Our inte-
gration process extracts all relations from these data-
bases through separate automated parsing routines
tuned for the format of each source database flat file. In
total, we extracted 4,945,372 primary database relations
between 2,312,423 compound/drug entries and 202,465
target entries (Table 1). These data were analyzed for re-
dundancy and combined with references to the primary
sources in the next stage of the integration process - the
unification.of a gene, a compound, and a relation between them supported by
s and therefore be of different types, may have references or assay
on procedures, links to source database entries, and multiple
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id-mapping of target entries and detection and merging of
chemical entries. The id-mapping of all target entries to
gene entries is based on a common index, the Entrez Gene
Index from NCBI [15]. Entities mapping to the same
NCBI gene are thereby merged while relations whose tar-
get cannot be unambiguously traced to a verified gene or
gene product are removed. Thus only protein and nucleo-
tide target entries are imported, while pseudogenes, meta-
bolic pathways, disease, and other more general types of
target entities are removed. As there are many published
or tested chemical compounds that lack unified identifiers
such as Chemical Abstracts Service Numbers (CAS
Number) or International Chemical Identifiers (InChI),
compound unification is a more complex process, and de-
pends on the information that is available about the com-
pounds in each source database. If chemical structures are
available they are extracted from Structure-Data Files
(SDF) [31] and passed through a series of purging rules
(i.e. removal of free water molecules and small independ-
ent ions, elimination of repeating molecules from poly-
mers, ignoring information about isotope composition,
dipolar bonds, and stereoisomerism). Purged structures
that are identical are subsequently merged. In contrast, if
no chemical structure is available we try to map the pro-
vided compound names to the entries created by our SDF
integration through cross-references between the source
databases. For example, if the compound aspirin from a
given database has a cross-reference to the entry acetyl-
salicylic acid in another database, then aspirin is merged
with acetylsalicylic acid. Finally, for compounds without
available chemical structure, or cross-reference between
source databases, we try to use other available identifiers
such as InChIKeys, brand names, compound formulas,
Simplified Molecular-Input Line-Entry System (SMILES),
or synonymous names for an exhaustive search which is
performed in a hierarchical order (see Additional file 1:
Table S1). If any of the identifiers matches a value from an
already processed compound then the two entries are
merged. The compounds that cannot be merged by above
steps are integrated as separate compound entries.
As a result of our gene mapping and compound unifi-
cation, evidences for a relation either collapse to a single
Drug2Gene entry if they refer to the same compound
and gene, or they create a unique Drug2Gene entry with
its respective evidence(s). The merging procedure be-
hind every composite entry is reflected in the unification
confidence provided to the user – with ‘high confidence’
assigned to SDF/InChI based, ‘medium confidence’ for
cross-reference-based, and ‘low confidence’ for name-
based merging. In addition, all relations are subject to a
reliability scoring system based on the type of evidence
supporting the relation in the source databases. For ex-
ample, computationally predicted evidences have a scoreof 4, measured interactions – 9, and highly curated in-
teractions (e.g. those of approved drugs) - 10. If the
interaction has more than one evidence, the highest
score is attributed to the entire relation.
Integrated entries are stored in Drug2Gene’s relational
database schema designed to meet the requirements of
the combined dataset as well as to normalize data com-
ing from different source databases (Additional file 2:
Figure S1). Drug2Gene is regularly updated every six
months.
Creation of homology-based relations
If a gene in an existing relation has an ortholog or para-
log with >80% amino acid sequence identity between the
encoded protein sequences (according to NCBI Homolo-
Gene) then a so called “homology-inferred relation” to
the same compound(s) is created for the corresponding
gene. Through this procedure we extend the scope of
imported relations by adding probable drug targets as
homology-based relations can suggest overlooked side ef-
fects (interactions) for a given compound or extend the
available set of active compounds for a given gene/protein
(see Case studies). All relations inferred by homology are
clearly earmarked with a red asterisk in the user interface
of Drug2Gene. In queries they can be intentionally disre-
garded or specifically selected through two dedicated
search indices (see User interface).
Standardization of evidences and classification of
relations
Besides the identification and merging of redundant
protein and compound data, another prerequisite for
efficient data-mining of compound-gene relations is
the direct comparability of binding measurements. To
this end the data fields “Activity Type”, “Activity
Value”, and “Activity Units” in Drug2Gene are sub-
jected to standardization.
We first normalize the types of activity found in the
source databases. For example, “Inhibitory Concentra-
tion” and active concentration “AC” are replaced by half
maximal inhibitory concentration “IC50” if the evidence
refers to inhibition. Once the activity types are standard-
ized we convert the measurements to standard units
according to International System of Units (SI). For in-
stance, if the data source reports values in micromoles,
then they are converted to the molar equivalents such as
207.2 μM to 0.0002072 M. In searches or for data ex-
ports only those standardized values are used. Changed
values are explicitly denoted in the interface with a SI
icon, which displays the original values upon click.
Activity measurements having constants like half max-
imal inhibitory concentration (IC50) or the binding affinity
(Ki) are not self-explanatory for users without experience
in the field of biochemistry, medicinal chemistry, or
Figure 2 Integration greatly decreases redundancy compared
to searching source databases independently. Whereas the
reduction of redundancy upon integrating data from 19 databases is
less prominent for relations (i.e. the different source databases have
little overlap (~12%) of relational information), it is very significant
especially for the compound space (~67% reduction). Given are
number of gene and compound entries and their relations before
and after integration together with the difference between these
values (the number of entries merged to already existing ones).
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those different activity types, we evaluated and assigned
them discrete and simple binding strength categories
(“strong”, “medium”, “weak”, or “no binding”) which we
call “Activity Strength”. To this end, the binding strength
of each evidence is evaluated according to its activity
value. While arbitrary, the applied cutoffs reflect best
practice values typically used in pharmaceutical indus-
try. For instance, IC50 values = < 10E-08 M get classified
as “strong”, values between 10E-08 and 10E-06 M –
classified as “medium”, and values between 10E-06 M
and 10E-05 M as “weak”. IC50 values > 10E-05 M are
considered unspecific and are set to “no” activity. Once
all evidences of a relation have been categorized, the re-
lation will inherit the “strongest” term assigned to any
of the evidences. We refer to this latter categorization
as the “Relation Strength”. Now, a user can just filter for
all “strong” interactions, or all relations with “Relation
Strength” > “weak” thus abstracting from the different
types of bioactivity measurements.
Results of data integration
Our data integration process unifies target and com-
pound entries. We extracted a total of 202,465 target
IDs from source databases which could be mapped by
our pipeline to 42,144 unique NCBI gene IDs. This cor-
responds to a ~79% condensation of the target space.
For compounds which participate in relations, unifica-
tion reduced the number of entries from an initial
2,312,423 entries in the source databases to 770,073
unique entries (~67% reduction) in the Drug2Gene data-
base (see Figure 2). Merging these entities automatically
leads to the unification of the corresponding drug-target
relations. From the original 4,945,372 source database
relations we have assembled 4,372,290 unified relations,
corresponding to a ~12% (573,082 entries) decrease (see
Figure 2). This decrease is due to an overlap between dif-
ferent relational source databases or from experiments for
identical gene-compound interactions within the same
source database. From the set of 4,372,290 unified relations
produced as a result of the id-mapping and compound
unification we predict an additional 226,513 homology-
inferred relations using the 43,071 gene homology groups
provided by the NCBI HomoloGene databases (Table 1).
After integration, we have 4,598,803 unique relations
between 42,144 genes and 770,073 compounds that are
available in version 3.2 of Drug2Gene.
Genes and compounds not participating in relations
are also deposited in Drug2Gene to make sure users
always identify a compound or gene in the database even
if only to learn there are no relations known so far.
Therefore we integrated all gene entries and all com-
pound entries from genetic (e.g. NCBI Gene, HGNC)
and chemical (ChEBI, NCBI PubChem) resources (seeAdditional file 1: Table S2). If these entries are counted,
the total number of targets before unification equals
12,168,716 and that of compounds 124,848,656. After in-
tegration they are reduced to 11,232,904 (~ 8% reduc-
tion) and 28,730,299 (~77% reduction) respectively (see
Additional file 3: Figure S2). These normalized compound
and gene namespaces are used during updates of the data-
base and for integration of new relational sources.
Utility and discussion
User interface
Drug2Gene provides an easy three-level web-interface
with a “Home page” that holds the search section, a
“Hit-list page” for results, and a “Final page” with three
entity-oriented views for inspection of specific relations
(see Figure 3). A horizontal navigation bar with links to
the “Home page” and four other sections (“Manage-
ment”, “Download”, “Contact”, and “Help”) is displayed
on the top of every page. Each search starts from the
search section of the “Home page”. This section has a
“Main search” and an “Alternative search” mode.
The “Main search” mode permits building complex
queries combining up to ten search fields in more than 40
different indices that characterize compound-target rela-
tions. Search fields can be combined with Boolean opera-
tors (“AND”, “OR”, “AND NOT”). Each index is searched
with a specific set of logical operators (“=”, “!=”, “>”, “<”,
“>=”, “<=”), defined by its type of data. For text indices the
operators “=” (equal) and “!=” (not equal) are available
with “strict” (results should match all terms of the search
Figure 3 Drug2Gene search workflow. The “three-click” search workflow of Drug2Gene consists of “Home page” (enter the search), “Hit-list
Page” (result table with option for further filtering, see also Figure 4 for details) and “Final page” (complete information of a single entry).
Each page is presented with the basic functionality it provides. The final page comes in three flavors: relation-centric, gene-centric, and
compound-centric. In the next version the hit list page will be accompanied by a network visualization. Results can be exported from the
hit-list page as well as from the final pages.
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terms provided). Some indices are enhanced with an auto-
complete function (Additional file 4: Table S3), which re-
veals their content to the user by suggesting actual values
from the indices upon typing. Above the search field the
user can also find a help icon which opens an info box
showing the type of values that can be entered for each
search index. Each field can be expanded to a multiline
mode to enter a list of search terms (e.g. all gene IDs of a
pathway or a list of compounds of a screen). The use of
the main search is illustrated with short examples in the
“Case studies” section.
The “Alternative search” has one input field for query
strings, either manually written to build more complex
and powerful queries or queries saved from previous ses-
sions. The query syntax is simplistic and intuitive, allowing
for searches unavailable or too cumbersome to create
using the “Simple search” functionality. The current query
string created either automatically by using the “Simplesearch” or explicitly with the “Alternative search” is always
displayed at the top of the “Hit list page”.
The “Hit-list page” provides functionality for effective
selection of subsets of target entries via a filter section
and a customizable “Results table” (Figure 4A and C).
The filter section is functionally identical to the search
section on the “Home page”, but applies the new search
criteria only on the previous results set. It also displays
the currently used query string that can be copied and
used in the “Alternative search” mode of the “Home
page”. The query syntax is consistent between Drug2-
Gene versions such that stored queries can be used for
documentation purposes or to retrieve an up-to-date re-
sult after the database has been updated.
The “Results table” has six columns by default, that
present the essential relational information about inter-
acting compounds and genes/proteins together with the
available activity information. The number and type of
columns in the table is configurable through the “select
Figure 4 The “Hit-list page”. A: Filter section (similar to the query interface with all available indices); B: Statistics section (to clarify how many
relations have been found between how many unique genes and compounds); C: “Results table” with export link (1), table configuration link to
add or remove further informative columns (2), and flagging link active only for registered users (3).
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table. Additional columns such as the compound struc-
ture can thus easily be added. The first column - “Rela-
tion ID”, contains the internal Drug2Gene ID of entries
and provides a “Show entry” button (Figure 4, C-4) that
leads to the “Final page” which displays, depending on
the user choice, either a relation, gene, or compound
centric view of the data (Figure 3). A red asterisk (*) next
to the ID denotes that the relation has been inferred by
homology. If entries are selected with the left-hand
check box, they can be exported through the export link
in one of the available formats (see “Import and export
functionality”). The last column in the “Results table”
comprises the evidences ordered into subcategories such
as activity values, displayed in base SI units. If the activ-
ity data had to be standardized after entering the data-
base, an interactive SI icon is displayed in front of it.
Evidences and relations can be flagged as true or false by
registered users with the respective rights. Each flag can
be supported by comments that are visible for all users
of the database. This option is developed with the idea
to improve and verify the publicly available relational
data through a crowd-sourcing effort.
The “Final page” (Figure 3) displays all available fields
for the database entry as well as all the available infor-
mation for the interacting partners and their relations in
one of the three views available through the “Show
entry” button.
Import and export functionality
Import and export of data are indispensable features for
a combined knowledge base like Drug2Gene. The im-
port allows the integration of new data sources and their
immediate comparison with the existing datasets. At thesame time the flexible export guarantees further usability
of data beyond the knowledge base.
The data import functionalities of Drug2Gene are situ-
ated in the “Management” link on the navigation bar at
the top of each page. They are accessible to registered
users and allow the import of relational, gene, and com-
pound data in XML, TSV, or SDF format. Sample files
are provided for each format. The maximum upload file
size is 20 MB and 50 files are allowed per single upload.
Batch file import and access to an import API without
those restrictions are available by request. Upon import
all relations are automatically subject to the unification
and standardization procedures of the database. The nor-
malized namespace of compounds and targets (including
those without known interactions) is used as a reference
during the import of new relations. All these features were
developed to handle large datasets. They are constantly
used within our IT infrastructure for the import of propri-
etary datasets.
The export dialog on the “Hit-list Page” (Additional
file 3: Figure S3) provides three types of options: export
format (XML, TSV, XLS, and SDF in a compressed or
uncompressed file), selection of result columns for the
export file, and selection of the range of exported results
(all results or just those selected by the user). An entry-
oriented export is also available in each view of the
“Final page” (Figure 3). If the “Compound Structure”
checkbox is selected, the molecular structure of com-
pounds participating in the selected relations is included
in the export file. The export of compounds to files in
SDF format is very useful as the structures can further be
used with chemoinformatics programs within various
drug development workflows. Structures of individual
compounds are also accessible in mol file format through
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column of the “Results table” and the corresponding cat-
egory on each view of the “Final page”.
Case studies
The search section of Drug2Gene provides a user-friendly
and flexible query building interface. It empowers scien-
tists of different research backgrounds to effectively search
for drug-target related data. The usefulness of Drug2Gene
is illustrated by several exemplary workflows described in
this section. More detailed step-by-step instructions to-
gether with the corresponding query strings are presented
in Additional file 5.
Searching interactions by compound name, formula, or
standard identifiers
For example, searching in the compound name index for
“zoledronate” returns 59 relations between 55 unique
genes and 2 compounds (zoledronate and its salt zoledro-
nate trisodium hydrate). Adding the ‘compound structure’
column to the “Result table” allows visual verification of
compound identities. The hit list includes evidences from
7 relational databases – CGDCP, ChEMBL, CTD, Drug-
Bank, PharmGKB, Pubchem BioAssay, and TTD. Their
activity types and values are now standardized (“SI” icon
in front of the evidence) and directly comparable in the
“Results table”. Click on the SI icons to see the original
values from the primary resources. If the user prefers only
chemically identical matches in the result list (e.g. only the
salt), the systematic name or any of the standard identi-
fiers (“InChI”, “InChIKey”, or “SMILES” indices) should
be used as a search term. For example a search for the
zoledronate salt ZK-thiazolidinone using its InChIKey
returns exactly one interaction. InChIKeys are fixed-
length character strings fully representing a molecular
compound structure. As strings (in contrast to com-
pound structures) can be used in internet search en-
gines they are a very useful start point for chemists or
chemoinformaticians to search for a certain compound
structure in Drug2Gene or the internet.
In contrast to zoledronate, 1-bromo-2,3-dihydroindole
is a compound with no relation data reported, still a user
finds the compound in Drug2Gene to distinguish be-
tween “compound was not found” and “compound was
found but no relations available”.
Finding all known compounds for a pathway
Researchers often need to quickly understand which com-
pounds are available for a set of genes (e.g. a signaling
pathway or the key enzymes of a metabolic pathway).
We start a search for compounds modulating the
“Tie2 Signaling” pathway. Pathway Commons provides a
list of Gene IDs for this pathway [32], which we enter in
the list option searching the ‘Entrez Gene ID’ index ofDrug2Gene. The query returns the overwhelming number
of 10,646 relations between 6,750 unique compounds and
18 genes. The data is derived from 15,462 evidences com-
ing from 11 primary databases. Most evidences have no
bioactivity data (8,684), whereas 6,778 evidences are based
on IC50 (3,466), percent inhibition (428), Ki (164), Kd
(268), or other activity types (2,452) still relating 4,916
unique compounds to 11 unique genes. Filtering by “Rela-
tion Strength” = “Strong” helps to focus conveniently only
on the 826 highly active compounds. We may further nar-
row down the results by filtering for subnanomolar inter-
actions using “Activity Value” < = “1E-09” referring to
IC50, EC50, Ki, or Kd (other notations are also accepted,
e.g. “0.000000001”, “0.1E-08”, or “10E-10”). This filter
returns 93 relations between 86 unique compounds and 6
unique genes. The data (incl. structures and bioactivities)
can now be exported as a file in SDF format and loaded
into a chemo-informatics workbench to analyze further by
chemical properties (e.g. compound similarity cluster-
ing, rule of 5, etc.). Another helpful use case showcasing
Drug2Gene’s functionality is to explore the target space
of a list of compounds, e.g. to evaluate high throughput
screening results or to search a whole cluster of struc-
turally similar compounds. We are not aware of any
other resource giving this depth of information within a
quick query.
Drug repositioning and predicting side effects
Following the slogan “Drug promiscuity for one can
open polypharmacological opportunities for the other”, a
very common task in drug repositioning (finding novel
applications for already approved drugs) is the exhaust-
ive search for interactions between a given compound
and all its intended as well as originally unintended tar-
gets (i.e. off-targets). Drug2Gene reduces considerably
the time required for gathering such information, which
normally is spread between many relational sources.
Thalidomide, a hypnosedative drug, originally pre-
scribed to pregnant women for morning sickness tragically
led to fetal malformation of the limbs due to its teratogen-
icity. The teratogenic effect arises supposedly through in-
hibition of angiogenesis. However, later Thalidomide was
found to be effective against leprosy and in treating mul-
tiple myeloma [33]. Searching Drug2Gene for “thalido-
mide” or its analogs (“pomalidomide”, “lenalidomide”),
reports 206 relations and 169 targets including CRBN, the
gene conveying thalidomides teratogenic effect. When fil-
tered for “Organism Name” = “Homo sapiens” AND “Re-
lation Strength” > = “Weak” (i.e. at least weak binding to
human targets) Drug2Gene selects only 20 relations be-
tween four compounds and 14 targets where bioactivity
has been convincingly evidenced. Some of these targets
are interesting starting points to elucidate the mechanism
of thalidomide in e.g. leprosy or multiple myeloma.
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novel avenues for a compound or predict side effects is
through its added value of homology-inferred relations.
An example illustrating this utility can be found in
Additional file 5 (Case study 3). It demonstrates the use
of Drug2Gene for the identification of novel inhibitors
for metalloproteinase enzymes in human.
Comparison with other knowledge bases
To our knowledge, the most comprehensive database
until now, STITCH, contains over 300,000 compounds
in interactions as well as protein interaction data from
1133 species [7]. Other aggregated knowledge bases (e.g.
SLAP [9] and PiHelper [13]) offer smaller interaction
datasets and restrict their scope to specific subsets of
compounds or biological species or optimize their selec-
tion of source databases to additional types of data like
protein-protein interactions, metabolic pathways, or drug
side-effects. In contrast, Drug2Gene aims at providing the
most comprehensive set of compound-gene/compound-
protein interactions. Currently it contains over 4 million
interactions between some 700,000 compounds and more
than 40,000 proteins from 1493 organisms (mostly from
human, mouse, and rat - see Additional file 3: Figure S4).
Importantly, aside from hosting public data, Drug2Gene
also allows the upload and integration of proprietary
drug-target information. In addition, Drug2Gene provides
a unique combination of data content, search functional-
ities, data export functionalities, and homology based
predictions. Its most differentiating feature is the strict
unification and standardization of all data allowing for
the first time to mine effectively and non-redundantly
over the full chemical and biological space including the
bioactivity-based evidences. Algorithms and decision
rules implemented within the database make use of this
standardization by evaluating each bioactivity data to
classify the binding strength. With this categorization in
place, even inexperienced users without detailed know-
ledge about IC50, Ki, or Kd may easily differentiate be-
tween affine or weak compounds.
Considering the search functionalities, Drug2Gene pro-
vides all major types of search options available in other
databases - an all text index as well as separate indices for
each data category. Instead of several single entity-oriented
search interfaces, Drug2Gene has a unique relation-
centered interface, which allows the combination of search
terms related to different types of entities - genetic, chem-
ical, and experimental. This innovative approach enables
the effective harnessing of specific subsets of relations
through step-by-step query building. The consecutive fil-
tering of initial search results using binding strength classi-
fication or detailed numerical evaluations like IC50 < 10
nM allows the user to assess the effect of each additional
criteria and adjust the query according to it. The searchsupports the full list of Boolean operators (including “AND
NOT”) for query construction. Also very complex queries
can be built using the “Alternative search” tab or by inter-
rogating Drug2Gene for a full gene and/or compound set
using the multiline search mode.
Another distinguishing feature of Drug2Gene is the
very flexible export of results available for result sets, for
selected entries, or in entry-oriented mode. The export
options completely release the data, including compound
structures, for use in custom pipelines or special purpose
(e.g. chemo-informatics) workflows.
Unlike alternative resources, homology-inferred rela-
tions in Drug2Gene are displayed whenever protein simi-
larity suggests a compound may also bind to a hitherto
unrelated protein. They can be searched through the indi-
ces “Homolog Organism” and “Homolog Similarity” and
accessed independently of the drug target relations under-
lying their creation.
Future development
Drug2Gene in its current version 3.2 still lacks some fea-
tures that can be found in other resources, e.g. (sub-)
structure-based similarity search many of which we will
address with the next release of Drug2Gene. For instance,
in the next release 4.0 the effectiveness of searching will
be enhanced by allowing to draw and search by chemical
structure as well as by structural similarity using Tanimoto
distance. Regarding the representation of hit lists we are
going to add a graphical network view that allows users to
quickly and intuitively navigate through the interaction
data, to identify common interaction targets, and to iden-
tify possible side-effects.
Conclusions
We have integrated 19 publicly available source data-
bases and developed a user friendly web-interface that
allows not only simple but also highly complex database
searches, covering a broad range of user requirements.
The current version of Drug2Gene (version 3.2) hosts
over 28 million compounds, some 11 million genes, and
more than 4 million compound-target interactions. All
integrated bioassay data is strictly standardized and nor-
malized, facilitating comparative meta-analyses. This ex-
tensive data collection is further extended by homology
inferred interactions that can be used e.g. for identifying
novel applications for known drugs or predicting un-
wanted side effects.
On top of this unprecedented data set, we provide ex-
tensive features for not only exporting the data in vari-
ous formats to facilitate subsequent incorporation into
third-party scientific research tools but also for upload-
ing user defined datasets.
All of the above mentioned transform the Drug2Gene
knowledge base into a ‘one-stop shop’ for identifying
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known targets of a drug or to evaluate the biology of the
compound hit list of a high-throughput drug screen.
Availability and requirements
The resource is freely available at http://drug2gene.com.
Crowd-sourcing features require registration to enable
flagging, annotation of Drug2Gene entries, or upload of
own data sets. Authenticated access is provided upon mo-
tivated request through the contact section of the site.
Due to hardware limitations, a limit of 10,000 entries per
single export for guest users exists. Download of larger
sets is available upon request (for registered users). All
other functionalities are completely accessible without
limitation or registration.
Additional files
Additional file 1: Table S1. Priorities of compound names during
compound unification. Table S2. Number of gene and compound
entries extracted from all source databases regardless their participation
in relations.
Additional file 2: Figure S1. MS SQL database diagram.
Additional file 3: Figure S2. The effect of integration for the entire
compound and gene namespaces (regardless their participation in
interactions). Figure S3. The option menus of the “Results table” on the
“Hit-list page”. Figure S4. Top-ten most populated species in Drug2Gene
by number of relations.
Additional file 4: Table S3. Search categories are used to query or
filter for a subset of the database.
Additional file 5: Drug2Gene case studies. Step-by-step instructions.
Search steps can be easily reproduced through the advanced query
strings provided after each case study.
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